Elicio Therapeutics, Inc. financial data

Symbol
ELTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
451 D Street, 5 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Angion Biomedica Corp. (to 5/30/2023)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 210 % -39.8%
Debt-to-equity -2.51K % -9122%
Return On Equity 4.26K % +5576%
Return On Assets -177 % -79.1%
Operating Margin -2.61K % -2183%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares +28.4%
Common Stock, Shares, Outstanding 10.8M shares +28.7%
Entity Public Float 47.1M USD +37.3%
Common Stock, Value, Issued 108K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +62.2%
Weighted Average Number of Shares Outstanding, Diluted 13.6M shares +62.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 653K USD -97.8%
Research and Development Expense 29.1M USD +101%
General and Administrative Expense 11.8M USD +58.2%
Costs and Expenses 40.9M USD +86.3%
Operating Income (Loss) -40.9M USD -73.3%
Nonoperating Income (Expense) -5.94M USD -181%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46.8M USD -42.4%
Earnings Per Share, Basic 18.5 USD/shares -9.45%
Earnings Per Share, Diluted 18.5 USD/shares -9.45%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26M USD +75.3%
Other Assets, Current 405K USD -12%
Assets, Current 30.6M USD +53.8%
Property, Plant and Equipment, Net 523K USD -32.3%
Operating Lease, Right-of-Use Asset 5.93M USD -12.4%
Other Assets, Noncurrent 864K USD +1008%
Assets 38.4M USD +23.9%
Accounts Payable, Current 1.98M USD -55%
Employee-related Liabilities, Current 1.47M USD -6.66%
Accrued Liabilities, Current 4.85M USD +9.87%
Contract with Customer, Liability, Current 1.31M USD -21.5%
Liabilities, Current 9.02M USD -21.5%
Operating Lease, Liability, Noncurrent 5.34M USD -14.1%
Other Liabilities, Noncurrent 81K USD
Liabilities 57.4M USD +224%
Accumulated Other Comprehensive Income (Loss), Net of Tax -202K USD -708%
Retained Earnings (Accumulated Deficit) -180M USD -35.2%
Stockholders' Equity Attributable to Parent -19M USD -243%
Liabilities and Equity 38.4M USD +23.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -48.9%
Net Cash Provided by (Used in) Financing Activities 11M USD +9.8%
Net Cash Provided by (Used in) Investing Activities 3K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 10.8M shares +28.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -158%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28M USD +63%
Deferred Tax Assets, Valuation Allowance 90.1M USD +223%
Deferred Tax Assets, Gross 47.2M USD +15.6%
Operating Lease, Liability 6.22M USD -13.1%
Depreciation 0 USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47M USD -83.3%
Lessee, Operating Lease, Liability, to be Paid 7.72M USD -16%
Property, Plant and Equipment, Gross 1.99M USD -8.88%
Operating Lease, Liability, Current 877K USD -6.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD +2.52%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.35M USD -5.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.51M USD -26.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 60.7M USD +217%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.1M USD -4.81%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +2.95%
Operating Lease, Payments 379K USD +21.5%
Additional Paid in Capital 161M USD +10%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.33M USD +13.5%
Interest Expense 753K USD -89.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%